Institutional Investors Must Be Pleased After a 7.3% Gain Last Week That Adds to Standard BioTools Inc.'s (NASDAQ:LAB) One-year Returns
Standard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024
Standard BioTools Shareholders Back Growth and Governance Plans
Standard BioTools Plans to Sell 105.1M Shares in Secondary Offering - Filing
TD Cowen Maintains Standard BioTools(LAB.US) With Buy Rating, Maintains Target Price $3.5
Express News | Standard BioTools Inc Files for Offering of up to 105.1 Mln Common Shares by the Selling Securityholders - SEC Filing
